Articles from Welldoc

Welldoc®, a leading AI-powered health tech company pioneering cardiometabolic care, today announced the expansion of its platform to include comprehensive support for the management of chronic kidney disease (CKD) and metabolic dysfunction-associated steatohepatitis (MASH). This expansion reinforces Welldoc’s commitment to delivering holistic, evidence-based AI-driven solutions that address the complex, interconnected nature of cardiometabolic conditions.

Welldoc®, a leading digital health company pioneering AI-driven cardiometabolic care, and Databricks, the Data and AI company, today announced the expansion of their strategic partnership.

Welldoc®, a digital health leader revolutionizing AI-driven cardiometabolic care, today announced its selection by Modern Healthcare as one of the 2025 Best Places to Work in Healthcare. This national award recognizes top employers in the healthcare industry.

Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lilly Health app) with its cardiometabolic digital health platform. The Lilly Health app is designed to support a tailored patient experience for individuals interested in or using Eli Lilly and Company’s incretin-based therapies, for the treatment of cardiometabolic conditions, such as obesity, type 2 diabetes and moderate- to-severe obstructive sleep apnea and obesity. Initially, the Lilly Health app will be available for patients prescribed Zepbound® (tirzepatide)** or Mounjaro® (tirzepatide)**.

Welldoc®, a digital health leader revolutionizing AI-driven cardiometabolic care, today announced that it has been selected as winner of the “Best Overall Digital Health Company” award for the third consecutive year in the MedTech Breakthrough Awards. The annual awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market. This is the fourth year that MedTech Breakthrough has recognized Welldoc for its leadership and innovation in the digital health industry.

Welldoc®, a digital health leader revolutionizing cardiometabolic care, announced today that it was Certified™ by Great Place to Work® for the fourth year in a row. This prestigious award recognizes companies with exceptional workplace cultures based solely on employee feedback. An impressive 94 percent of employees said Welldoc is a great place to work, exceeding the U.S. average by 37 points.

Welldoc®, a digital health leader revolutionizing cardiometabolic care, today announced that it has been named a winner in the 2025 Artificial Intelligence Excellence Awards program presented by the Business Intelligence Group. The Artificial Intelligence Excellence Awards recognize groundbreaking advancements in AI and companies that have demonstrated a commitment to innovation and significant measurable impact.

Welldoc®, a digital health leader revolutionizing cardiometabolic care, today announced the issuance of four new patents, marking its 54th patent grant. This milestone underscores Welldoc’s relentless commitment to innovation and leadership in leveraging artificial intelligence (AI) and advanced predictive capabilities based on real-time sensor data. The company’s digital health platform empowers individuals with personalized AI-driven digital coaching to enable self-management of cardiometabolic conditions, positive lifestyle changes and improved overall health and outcomes.

Welldoc®, a leading digital health company specializing in AI-driven cardiometabolic health, today announced significant advancements in its AI research strategy, focused on responsible AI integration in healthcare. The company presented a series of clinical publications on the application of its novel generative AI model designed to improve health outcomes through predictive analytics at leading industry conferences throughout October, including FNCE, DTM and INFORMS. This research expands upon Welldoc's impressive portfolio of 37 AI-focused publications, solidifying the Company’s leadership in developing responsible and judicious AI solutions for healthcare.

Welldoc, a leading digital health company specializing in AI-driven cardiometabolic health, today announced a collaboration with Instacart, the leading grocery technology company in North America, to transform healthcare delivery for health plans and members by bridging the gap between nutrition and health. Through enhanced access to quality care and nutritious food, Welldoc aims to improve health outcomes and reduce overall costs of care for individuals managing cardiometabolic conditions.

Welldoc®, a leading digital health company specializing in AI-driven cardiometabolic health, announced today that it was Certified™ by Great Place to Work® for the third consecutive year. This prestigious award recognizes companies with exceptional workplace cultures based solely on employee feedback. An impressive 90 percent of employees said Welldoc is a great place to work, exceeding the U.S. average by 31 points.

Welldoc®, a leading digital health company specializing in cardiometabolic health, today announced that it has been selected as winner of the “Best Overall Digital Health Company” award for the second consecutive year in the 8th annual MedTech Breakthrough Awards. The awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market. This is the third year that MedTech Breakthrough has recognized Welldoc for its leadership and innovation in the digital health industry.

Welldoc, a leading digital health company specializing in cardiometabolic health, today announced that its flagship BlueStar® mobile app has received CE mark certification as a Class IIa medical device under the European Union Medical Device Regulation (EU-MDR). This significant achievement allows Welldoc to apply the CE mark to their medical device software. It also enables the company and their strategic partners to advance digital health solutions in the EU, addressing chronic condition needs that are rising globally. This announcement builds upon Welldoc's existing 11 FDA clearances for type 1 and type 2 diabetes management capabilities, including advanced insulin dosing calculators. This milestone underscores the company’s continued commitment to the highest standards of quality, while also demonstrating extensive leadership in AI-based digital health solutions.

Welldoc®, a digital health leader revolutionizing chronic care, today announced data demonstrating that the use of a digital health application in a virtual program for individuals with type 2 diabetes was associated with significant improvements in weight loss, as well as favorable trends in post-meal blood glucose and systolic blood pressure. The data, which were presented as a clinical research poster at the 18th Annual Cardiometabolic Health Congress in Boston, capture the results of a real-world study in which individuals were given access to the Welldoc App, which provides continuous AI-driven digital coaching designed to support self-management behaviors.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the expansion of its platform to support weight management. Welldoc’s comprehensive chronic care platform now provides multi-condition support across prediabetes, diabetes, hypertension, heart failure and weight management, along with integrated mental wellbeing and sleep apnea support. Welldoc’s weight management solution is currently available to all customers and will be launching in early 2024 with two of the leading health care companies in the U.S.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar®. This clearance immediately follows Welldoc’s 10th 510(k) clearance announcement earlier this month, solidifying the company’s continued leadership in chronic care innovation.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the receipt of its 10th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar®. This clearance reinforces Welldoc’s position as a leader in technology in diabetes management.

Welldoc®, a digital health leader revolutionizing chronic care, today announced that it has been selected as “Best Overall Digital Health Company” in the 7th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market. In 2022, MedTech Breakthrough selected Welldoc as winner of the “Best Overall Connected Healthcare Solution” award.

Welldoc®, a digital health leader revolutionizing chronic care, today announced that it has been named a winner in the 2023 Artificial Intelligence Excellence Awards program presented by the Business Intelligence Group. The Artificial Intelligence Excellence Awards recognize organizations, products and people who bring AI to life and apply it to solve real problems.

Welldoc®, a digital health leader revolutionizing chronic care, today announced that it has been named a winner in the 2023 BIG Innovation Awards presented by the Business Intelligence Group.

Welldoc®, a digital health leader revolutionizing chronic care, today announced that Anand Iyer, PhD, MBA, Chief Analytics Officer of Welldoc, was recognized with the Global Innovator Award at the Global Digital Health Summit, Expo & Innovation Awards. Presented on October 29 in New Delhi, India, the Global Digital Health Innovation Awards honored leaders who are driving digital health innovation across healthcare.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the appointment of Simon Salgado as Chief Revenue Officer. In this role, Salgado will lead commercial growth across health plans, health systems and employers, empowering more people living with chronic conditions to access Welldoc’s digital health platform which enables improved health and outcomes.

Welldoc®, a digital health leader revolutionizing chronic care, today announced it has been recognized as one of Fortune’s Best Workplaces in Health Care™ 2022. Welldoc was ranked in the top 50 Small and Medium Workplaces in Health Care.

Welldoc®, a digital health leader revolutionizing chronic care, today announced that the company’s 31st patent was granted on June 14, 2022, demonstrating the continued advancement of Welldoc’s first-in-class technology for comprehensive chronic condition management. Welldoc’s portfolio includes patents from the U.S. Patent and Trademark Office and IP Australia.

Welldoc®, a digital health leader revolutionizing chronic care, today announced that it was Certified™ by Great Place to Work®. The prestigious award is based entirely on feedback from current employees regarding their experience working at Welldoc. This year, 95 percent of employees said Welldoc is a great place to work – 36 points higher than the average U.S. company.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the presentation of data at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), evaluating how the combination of real-time CGM (rtCGM) with a digital health solution impacts glucose control for individuals with Type 2 diabetes not treated with insulin. For all participants and subgroups that were examined, the time in range (TIR) and glucose management indicator (GMI) improved significantly, demonstrating that a combined CGM and digital therapeutic solution has the potential to improve Type 2 diabetes management and glycemic control.

Welldoc®, a digital health leader revolutionizing chronic care, today announced that the company’s 25th patent was approved by the U.S. Patent and Trademark Office on December 8, 2021.

Welldoc, a digital health leader revolutionizing chronic care, today announced the receipt of its ninth 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes platform, BlueStar®. The new clearance expands insulin dosing support to most types of insulin, including Bolus and Premixed Insulin titration for type 2 diabetes. In June 2020, Welldoc announced FDA clearance for the BlueStar Insulin Adjustment Program for basal insulin titration. Welldoc’s previous FDA clearances for its advanced Artificial Intelligence (AI) capabilities and enhanced product features support the company’s continued efforts to simplify complex diabetes management.

WPS Health Insurance and WPS Health Plan selected Welldoc®, a trailblazer in digital health, to offer a new, comprehensive chronic conditions digital health solution to a pilot group of self-funded employers in Wisconsin and Illinois.

Welldoc®, a trailblazer in digital health that is revolutionizing chronic condition management to help transform lives, today announced that the company’s 20th U.S. patent was granted by the U.S. Patent and Trademark Office on April 13, 2021.